ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of ~$200M 2026 Buyback Plan
ADMA sits 18% above its 52-week low of $13.5 on elevated volume (1.8× avg).
Summary
ADMA Biologics has announced a significant capital return initiative, launching a $125 million accelerated share repurchase (ASR) program with JPMorgan. This ASR is part of a broader plan to repurchase approximately $200 million of common stock throughout 2026, funded via borrowings under its $225M revolving credit facility. The company will initially receive about 6.4 million shares. This move follows the company's recent report of record full-year 2025 financial results, including strong revenue and Adjusted EBITDA growth, indicating a robust financial position. The substantial share repurchase program signals management's confidence in the company's valuation and commitment to enhancing shareholder value, making it a material event for investors.
At the time of this announcement, ADMA was trading at $15.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $13.50 to $25.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Unknown.